integrin antagonists (Zeneca)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameintegrin antagonists (Zeneca)
Drug Alias Namefibronectin antagonists (Zeneca)VCAM antagonists (Zeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular cell adhesion molecule 1 inhibitorsIntegrin antagonists
TargetsVascular cell adhesion molecule 1Integrin
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesZeneca Group Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZeneca Group Plc
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A